These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 23499926)
1. Recombinant proteins that trigger production of antibodies recognizing botulinum neurotoxin while not possessing sequences of this toxin. Zdanovsky A; Zdanovskaia M Toxicon; 2013 Jun; 67():63-70. PubMed ID: 23499926 [TBL] [Abstract][Full Text] [Related]
2. Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A. Atassi MZ; Dolimbek BZ; Steward LE; Aoki KR Immunol Lett; 2012 Feb; 142(1-2):20-7. PubMed ID: 22123395 [TBL] [Abstract][Full Text] [Related]
3. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824 [TBL] [Abstract][Full Text] [Related]
4. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin. Oshima M; Aoki KR; Atassi MZ Immunobiology; 2014 Dec; 219(12):950-7. PubMed ID: 25151501 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the epitope region of F1-2 and F1-5, two monoclonal antibodies to Botulinum neurotoxin type A. Scotcher MC; Johnson EA; Stanker LH Hybridoma (Larchmt); 2009 Oct; 28(5):315-25. PubMed ID: 19857112 [TBL] [Abstract][Full Text] [Related]
6. [Screening of botulinum neurotoxin type A-binding peptides by phage display peptide library]. Shi J; Wang H; Yin J; Hou XJ Wei Sheng Wu Xue Bao; 2006 Feb; 46(1):136-8. PubMed ID: 16579481 [TBL] [Abstract][Full Text] [Related]
7. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Atassi MZ; Oshima M; Dolimbek BZ; Aoki KR Immunobiology; 2012 Jan; 217(1):1-7. PubMed ID: 22015045 [TBL] [Abstract][Full Text] [Related]
8. Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates. Atassi MZ; Naqvi M; Dolimbek BZ; Aoki KR J Neuroimmunol; 2014 Jul; 272(1-2):29-34. PubMed ID: 24841626 [TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library. Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786 [TBL] [Abstract][Full Text] [Related]
10. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573 [TBL] [Abstract][Full Text] [Related]
11. Epitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain). Scotcher MC; McGarvey JA; Johnson EA; Stanker LH PLoS One; 2009; 4(3):e4924. PubMed ID: 19290051 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121 [TBL] [Abstract][Full Text] [Related]
14. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Chen F; Kuziemko GM; Amersdorfer P; Wong C; Marks JD; Stevens RC Infect Immun; 1997 May; 65(5):1626-30. PubMed ID: 9125539 [TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Amersdorfer P; Wong C; Chen S; Smith T; Deshpande S; Sheridan R; Finnern R; Marks JD Infect Immun; 1997 Sep; 65(9):3743-52. PubMed ID: 9284147 [TBL] [Abstract][Full Text] [Related]
16. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Oshima M; Deitiker P; Jankovic J; Aoki KR; Atassi MZ Immunobiology; 2016 Apr; 221(4):568-76. PubMed ID: 26701846 [TBL] [Abstract][Full Text] [Related]
17. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Amersdorfer P; Wong C; Smith T; Chen S; Deshpande S; Sheridan R; Marks JD Vaccine; 2002 Feb; 20(11-12):1640-8. PubMed ID: 11858873 [TBL] [Abstract][Full Text] [Related]
18. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Atassi MZ; Dolimbek BZ Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181 [TBL] [Abstract][Full Text] [Related]
19. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Wu HC; Yeh CT; Huang YL; Tarn LJ; Lung CC Appl Environ Microbiol; 2001 Jul; 67(7):3201-7. PubMed ID: 11425742 [TBL] [Abstract][Full Text] [Related]
20. The role of structure in antibody cross-reactivity between peptides and folded proteins. Craig L; Sanschagrin PC; Rozek A; Lackie S; Kuhn LA; Scott JK J Mol Biol; 1998 Aug; 281(1):183-201. PubMed ID: 9680484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]